(Stroke. 1995;26:2302-2306.)
© 1995 American Heart Association, Inc.
Articles |
Cerebral Vasoreactivity Assessed With Transcranial Doppler and Regional Cerebral Blood Flow Measurements
Dose, Serum Concentration, and Time Course of the Response to Acetazolamide
From the Department of Neurology (D.R., R.N.-H., E.K.) and Institute for Clinical Biochemistry (K.R.), Rikshospitalet, The National Hospital, University of Oslo, and the Department of Neurology (A.D.), University Hospital, Tromsø, Norway.
Correspondence to Arve Dahl, MD, Department of Neurology, University Hospital, 9038 Tromsø, Norway.
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Background and Purpose To improve the assessment of cerebral vasoreactivity using acetazolamide (ACZ), we studied the time course of the response and the relationship between dose, response, and serum concentration.
Methods Blood flow velocities were measured with the use of transcranial Doppler ultrasonography in one of the middle cerebral arteries of 48 healthy subjects after the intravenous administration of 1 to 1.6 g ACZ. In 34 subjects (group 1), velocities were measured every second minute to detect the maximum middle cerebral artery velocity increase. We also measured regional cerebral blood flow using single-photon emission computed tomography in 27 of the subjects in group 1 before and approximately 15 to 20 minutes after the ACZ injection. The serum concentration of ACZ was measured in 15 subjects. In the remaining 14 subjects (group 2), middle cerebral artery velocity measurements were made 10, 25, 30, and 45 minutes after ACZ administration to obtain information regarding the late time course of the response.
Results In group 1 the plateau phase of the velocity response was reached 8 to 15 minutes after ACZ administration. A large range of velocity increase was observed, and a significant correlation was found between the maximum velocity increase and the dose and serum concentration of ACZ. In group 2 subjects, maximum velocities were maintained 30 minutes after the injection, but after 45 minutes velocities had decreased to 68% of their highest level. No significant relationship was found between dose or serum concentration of ACZ and the regional cerebral blood flow increase. The velocity increase after ACZ was similar in both older and younger subjects.
Conclusions This study shows that cerebral vasoreactivity is best assessed 10 to 30 minutes after ACZ administration and that the dose should probably exceed 15 mg/kg if a maximum vasodilatory response in the cerebral circulation is to be obtained.
Key Words: acetazolamide • blood flow velocity • cerebral blood flow • ultrasonics
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Information regarding the reserve capacity of the cerebral circulation has prognostic significance in patients with carotid artery occlusive disease.1 2 This information may be obtained by measuring changes in rCBF or blood flow velocities in the basal cerebral arteries after the administration of a potent vasodilatory stimulus such as ACZ or CO2.3 4 5 6 ACZ, which is a carbonic anhydrase inhibitor, has been studied quite extensively,7 8 but some important practical information is still lacking when this substance is used in vasoreactivity studies. This includes information regarding the optimal dose and the time course of the vasodilatory response.
A standard dose of 1 g IV ACZ, usually administered in adult patients, is assumed to cause a high enough inhibition of carbonic anhydrase to allow a good estimation of cerebral vasodilatory reserve. However, some investigators have given considerably higher doses, up to 22 mg/kg.9 To our knowledge, no studies have been designed to determine the dose of ACZ required to cause a maximal vasodilatory response. This is important since we want to bring about maximal vasodilatation without causing unnecessary discomfort for the patient. Maximal cerebral vasodilatation is, on the other hand, probably important if the assessment of cerebral vasoreactivity is to have a high diagnostic sensitivity.
The first aim of this study was to obtain information regarding the relationship between the ACZ dose and the serum concentration required to bring about a maximum vasodilatory response when the latter was measured by rCBF with dynamic SPECT and 133Xe inhalation. MCA blood flow velocities were measured with the use of TCD. The second aim was to record the time course of the response to obtain information regarding when rCBF and TCD measurements should be performed after ACZ administration.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Forty-eight healthy subjects (23 men and 25 women; age, 23 to 74 years; mean, 41.8 years) took part in the study after giving informed consent. They were divided into two groups. Group 1 included 34 subjects. Vasoreactivity was studied in these subjects with the use of SPECT, and maximum MCA velocity was measured, with particular attention paid to the early response after ACZ administration. In the 14 subjects of group 2, blood flow velocity measurements were performed between 10 and 45 minutes after ACZ administration to obtain information regarding the time course of the vasodilatory response beyond 15 minutes.
TCD Examinations
Blood flow velocities were measured in the left or right MCA
with the use of a TCD instrument (TC 2-64B, Eden/Nicolet Inc). The
instrument and the procedure for artery identification have been
described elsewhere.10 A permanently fixed 2-MHz probe was
used in 26 subjects and a hand-held probe in 22. Time-mean
velocities from the spectral outline were recorded.
We calculated mean velocity values from velocity samples using the mean of at least 10 to 15 heart cycles. In group 1, measurements were made at the end of the ACZ injection and repeated 2, 4, 6, 8, 10, 12, and 15 minutes later or until no further increase in velocity was observed. Measurements were therefore not usually performed after 15 minutes if there was no increase or a drop in velocities was observed from 10 to 12 minutes. In group 2, MCA velocities were measured before ACZ injection and again 10, 15, 20, 25, and 45 minutes after.
rCBF Measurements
rCBF measurements were performed in 27 subjects from group 1
before and from 15 to 20 minutes after ACZ administration. This was
carried out with the use of SPECT and 133Xe inhalation
(Tomomatic-64, Medimatic Inc). This instrument and method have been
described in detail elsewhere.11 12 rCBF was calculated in
milliliters per 100 g per minute in standardized regions of interest
corresponding approximately to the estimated perfusion territories of
the MCAs. The measurements were carried out in a 2-cm-thick slice
located 6 cm above the orbitomeatal line. A software package for
automatic calculation of flow values in regions of interest was used
for this purpose.12
ACZ Administration
Twenty-eight subjects in group 1 received 1 g ACZ. The
remaining 6 received doses from 1.0 to 1.6 g so that the vasodilatory
effect of higher ACZ doses could be studied. All subjects in group 2
were given 1 g ACZ. ACZ was injected intravenously during a
3-minute period after the subject had been resting for at least 5
minutes in the supine position.
Dosage and Serum Concentration of ACZ Measurements
Blood samples were taken from an antecubital vein contralateral
to the side of the injection in 15 of the subjects in group 1 who
received a standard dose of 1 g ACZ. The first sample was taken 5
minutes after the injection and the second immediately after the second
rCBF measurement. This was approximately 20 minutes later in 9
subjects, 25 minutes later in 5, and 30 minutes later in 1. The whole
blood was centrifuged within 1 hour and the serum frozen for
later analysis. The drug concentration in serum was
analyzed with the use of reverse-phase
high-performance liquid
chromatography.13
Statistical Evaluation
All values are given as mean±SD. All statistical tests were
two-tailed, and differences were considered statistically
significant at P
.05. Correlations between variables
were analyzed with the Pearson correlation model. Linear
regression analyses were also performed.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Mean blood flow velocities before the ACZ injection in group 1 were 63.5±13.5 cm/s; the maximum increase in velocity was 43.4±10.5%. The maximum velocity increase in group 1 (n=34) was reached 6 minutes after the ACZ injection in 3 subjects, 8 minutes after in 7 subjects, 10 minutes after in 15 subjects, and 12 minutes after in 9 subjects.
Fig 1
shows the time course of the ACZ response in group
1. The velocity increases as a percentage of baseline values are used
in the plot. In 29 of the 34 subjects a velocity increase was observed
before completion of the 3-minute ACZ injection, with a rapid velocity
increase during the next 6 to 10 minutes. Values then remained stable
until the rCBF study.
|
In group 2 the MCA velocities remained stable for approximately 30 minutes. However, 45 minutes after ACZ administration the mean response had decreased to 68% of the maximum level, a response that was significantly different from the values at 30 minutes (P<.01).
In 27 subjects studied with SPECT, basal rCBF (means of both sides) was 54.5±7.2 mL/100 g per minute, and the increase in flow was 14.8±5.0 mL/100 g per minute, which was an increase of 27.0±8.6%.
In 15 subjects the serum concentration of ACZ after 5 minutes was 107.6±17.7 mg/L; concentration at the second measurement (after 20 to 25 minutes) was 71.0±14.7 mg/L. In each subject the two values were closely related, with a correlation coefficient of .86. In 5 subjects the second blood sample was taken after 25 minutes and in 1 after 30 minutes. In these subjects we assumed that the serum concentration fell at the same rate between 20 and 25 minutes as it did in the previous 15 minutes. We therefore interpolated the assumed value for 20 minutes after injection in these 6 subjects and plotted these values against the 5-minute value. The correlation coefficient between the two serum concentrations then increased to .97. This strongly suggests that the relative differences in serum concentrations between the 15 subjects were preserved throughout the study period.
The relationship between the dose in milligrams per kilogram and the
serum concentration measured in the samples taken 5 minutes after ACZ
administration was close and the correlation coefficient
(r=.835) statistically significant (P<.001) (Fig 2).
|
Fig 3 shows the relationship between the dose in
milligrams per kilogram and the maximal MCA velocity response measured
with TCD. A significant linear correlation was found, and the plot
shows that within the small dose range assessed in this study the
highest response was found in the subjects who received the highest
doses. The plot suggests that a standard dose of 1 g to subjects who
weigh more than 70 kg (14.3 mg/kg) is insufficient to provoke a maximal
vasodilatation.
|
A significant relationship was also found between maximum velocity
increase and the serum concentration measured 5 minutes after ACZ
injection (Fig 4).
|
No significant correlation was found for rCBF increase in the MCA perfusion territory, in absolute values or in percentage, between the dose of ACZ or serum concentration.
There was no significant correlation between the percent velocity increase after ACZ administration and the age of the subjects (r=.09, P=NS). A significant negative correlation with age was found for rCBF increases (r=-.62, P<.001).
In all but 3 subjects the side effects of ACZ were slight and consisted of slight paresthesia in the extremities and perioral region. In 3 subjects the adverse effects were more severe and consisted of a diffuse headache, which required treatment with acetaminophen. These 3 subjects received more than 18 mg/kg of ACZ.
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
ACZ inhibits carbonic anhydrase, which reversibly catalyses the conversion of CO2+H2O to H2CO3. The effects of ACZ on the brain have been studied extensively.14 15 16 17 18 19 20 21 It increases the H+ and CO2 concentration in the extracellular fluid of the brain, which is assumed to be the stimuli for the increase in flow.22 Carbonic anhydrase is found inside the glial cells and in the plexus choroideus but is especially richly distributed in the endothelial cells of the brain capillaries, probably at the luminal side of the cell membrane.23 ACZ penetrates slowly through the blood-brain barrier, and the almost immediate increase in flow velocity observed in this study suggests that inhibition at the capillary endothelium is important when decreasing pH in the extracellular fluid of the brain.24 25
The dose-response curve suggests that in many subjects a dose below 15 mg/kg is insufficient to give maximum cerebral vasodilatation. Our study was not designed to determine where the dose-response curve levels off, but doses above 18 mg/kg seemed to increase the risk of unpleasant side effects. The dose should therefore preferably be at the level of 15 to 18 mg/kg. The relationship between dose and response found in our study indicates that a higher dose is needed to obtain maximal vasodilatation of the brain capillaries than that needed to obtain maximal effect on intraocular pressure, where 5 mg/kg as a single injection seems to give a near-maximal effect.26
At the time of the present study, information was incomplete regarding the time course of the response after ACZ administration. In one study in which Doppler measurements were taken of the carotid artery on the neck, a maximum response was observed after 25 minutes. Studies in which rCBF measurements with 133Xe have been used conflict regarding the rate of flow increase.14 15 16 We therefore studied the relationship between the serum concentration and the response in proximity to the beginning of the suspected flow/velocity increase and again close to the second rCBF study. We found that ACZ has a similar rate of elimination from serum in the first 20 minutes after an intravenous injection in all subjects. The most likely explanation for the observed fall in serum concentration is distribution of the drug from the blood to other body fluids (different compartments). Although the elimination of ACZ from serum follows a nonlinear model, animal studies have demonstrated that the drug disappears very quickly from plasma in the first 60 minutes before the plasma concentration levels out.25 27 The elimination constant was also very similar in different animal species. The relationship between the two measurements in our study was so close that the relative differences in drug concentrations between subjects seem to be preserved throughout the 20-minute period. These findings suggest that the concentration-dose responses may also be calculated for the 5- to 20-minute interval after administration.
TCD provides the opportunity to continuously follow the time course of a pharmacological stimulus on the cerebral circulation. This information is impossible to obtain with rCBF measurements with radioactive xenon. The effect of ACZ was seen very soon after the start of injection. In this study the maximum effect was reached earlier than reported by Hauge et al,16 who administrated ACZ 0.5 g IV and measured the velocity increase in the internal carotid artery in the neck. Slowness in achieving a high enough ACZ concentration in the target cells when a lower dose is used may explain their somewhat delayed response. The time course of the response observed in the present study is similar to that observed regarding the pressure-reducing effect in the eye.26 This suggests that vasoreactivity may first be assessed 10 minutes after ACZ administration and that it should be performed during the next 20 minutes. In the next 15 minutes, asymmetries may possibly be evaluated, but the response is no longer maximal.
In our study we did not find any significant relationship between dose and response when performing rCBF measurements with SPECT. One possible explanation for this is the precision of the method used. Assessing vasoreactivity with the use of SPECT and xenon inhalation is dependent on two rCBF measurements of absolute flow in milliliters per 100 g per minute. However, it is difficult to achieve precise measurements of absolute flow values because of methodological problems.28 29 Measurement of the increase in flow velocities during a 15-minute period, with subjects supine and with the use of fixed Doppler probes or repeated hand-held measurements, seems to be more precise than two rCBF measurements.28 30 It may therefore be easier to discover a relationship between vasoreactivity and dose with TCD rather than rCBF measurements with the use of SPECT and xenon inhalation.
This study also demonstrated that the increase in velocity after ACZ is similar in both older and younger subjects. Although the number of older subjects was small, this finding supports the use of ACZ when vasoreactivity is assessed in this age group. Højer-Pedersen,31 using ACZ and measuring rCBF with stationary detectors, found that the vasodilatory response appeared unchanged with advancing age. However, others have found a reduced response with age when using CO2 as the vasodilatory stimulus.32 33 We have no good explanation for the discrepancy between the TCD and rCBF findings regarding the ACZ response in older subjects. Both methodological and physiological explanations are possible. The TCD method measures blood flow velocities that are dependent on volume flow in the distribution territory of the vessel under study and the diameter of the vessel. A possible explanation is that the increase in flow after ACZ measured with SPECT may be influenced by factors that differ in older and younger subjects (for example, possible shunting of blood in the microcirculation after ACZ). In addition, since the measurements were not performed simultaneously in the present study, physiological factors may have differed during the two study situations.
In conclusion, the results from this study suggest that an ACZ dose of 15 to 18 mg/kg IV should be given when cerebral vasoreactivity is evaluated and that measurements of the vasoreactive response may be performed between 10 and 30 minutes after ACZ administration.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
We thank Cyanamid of Great Britain Ltd, Product Research and Development Laboratory, Medical/Agricultural Research Division, for developing the method used for the serum analysis of ACZ and for performing the measurements in this study.
Received June 22, 1995; revision received September 4, 1995; accepted September 7, 1995.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
1. Kleiser B, Widder B. Course of the carotid artery occlusions with impaired cerebrovascular reactivity. Stroke. 1992;23:171-174.
2. Yonas H, Smith HA, Durham SR, Pentheny SL, Johnson DW. Increased stroke risk predicted by compromised cerebral blood flow reactivity. J Neurosurg. 1993;79:483-489. [Medline] [Order article via Infotrieve]
3.
Vorstrup S, Brun B, Lassen NA. Evaluation of
the cerebral vasodilatory capacity by the acetazolamide
test before EC-IC bypass surgery in patients with occlusion of the
internal carotid artery. Stroke. 1986;17:1291-1298.
4.
Russell D, Dybevold S, Kjartansson O, Nyberg-Hansen R,
Rootwelt K, Wiberg J. Cerebral vasoreactivity and blood flow
before and 3 months after carotid
endarterectomy. Stroke. 1990;21:1029-1032.
5.
Ringelstein EB, Sievers C, Ecker S, Schneider PA, Otis
SM. Noninvasive assessment of CO2-induced cerebral
vasomotor response in normal individuals and patients with internal
carotid artery occlusions. Stroke. 1988;19:963-969.
6.
Dahl A, Lindegaard K-F, Russell D, Nyberg-Hansen R,
Rootwelt K, Sorteberg W, Nornes H. A comparison of
transcranial Doppler and regional cerebral blood flow
used to assess cerebral vasoreactivity in cerebrovascular
disease. Stroke. 1992;23:15-19.
7.
Maren HM. Carbonic anhydrase: chemistry,
physiology, and inhibition. Physiol Rev. 1967;47:595-781.
8. Wistrand PJ, Lindqvist A. Design of carbonic anhydrase inhibitors and the relationship between the pharmacodynamics and pharmacokinetics of acetazolamide. In: Botré F, Gros G, Storey B, eds. Carbonic Anhydrase: From Biochemistry and Genetics to Physiology and Clinical Medicine. VCH Verlagsgesellschaft: Weinheim, Germany; 1991:352-374.
9. Sullivan HG, Kingsbury TB, Morgan ME, Jeffcoat RD, Allison JD, Goode JJ, McDonnell DE. The rCBF response to Diamox in normal subjects and cerebrovascular disease patients. J Neurosurg. 1987;67:525-534. [Medline] [Order article via Infotrieve]
10. Aaslid R, Markwalder TM, Nornes H. Noninvasive transcranial Doppler ultrasound recordings of flow velocity in basal cerebral arteries. J Neurosurg. 1982;57:769-774. [Medline] [Order article via Infotrieve]
11. Stokely EM, Sveinsdottir E, Lassen NA, Rommer P. A single photon dynamic computer assisted tomograph (DCAT) for imaging brain function in multiple cross sections. J Comput Assist Tomogr.. 1980;4:230-240. [Medline] [Order article via Infotrieve]
12. Rootwelt K, Dybevold S, Nyberg-Hansen R, Russell D. Measurement of cerebral blood flow with Xe-133 inhalation and dynamic single photon emission computed tomography: normal values. Scand J Clin Lab Invest Suppl.. 1986;184:97-105. [Medline] [Order article via Infotrieve]
13. Chambers DM, White MH, Kostenbauder HB. Efficient extraction and reversed-phase high-performance liquid chromatography-ultraviolet quantisation of acetazolamide in serum. J Chromatogr. 1981;225:231-235. [Medline] [Order article via Infotrieve]
14. Vorstrup S, Henriksen L, Paulson OB. Effect of acetazolamide on cerebral blood flow and cerebral metabolic rate for oxygen. J Clin Invest. 1984;74:1634-1639.
15. Friis ML, Paulson OB, Hertz MM. Carbon dioxide permeability of the blood-brain barrier in man: the effect of acetazolamide. Microvasc Res. 1980;20:71-80. [Medline] [Order article via Infotrieve]
16. Hauge A, Nicolaysen G, Thoresen M. Acute effects of acetazolamide on cerebral blood flow in man. Acta Physiol Scand. 1983;117:233-239. [Medline] [Order article via Infotrieve]
17. Wang Q, Paulson OB, Lassen NA. Indomethacin abolishes cerebral blood flow increase in response to acetazolamide-induced extracellular acidosis: a mechanism for its effect on hypercapnia. J Cereb Blood Flow Metab. 1993;13:724-727. [Medline] [Order article via Infotrieve]
18.
Friberg L, Kastrup J, Rizzi D, Jensen JB, Lassen
NA. Cerebral blood flow and end-tidal Pco2
during prolonged acetazolamide treatment in humans.
Am J Physiol. 1990;258:H954-H959.
19. Heuser D, Astrup J, Lassen NA, Betz E. Brain carbonic acid acidosis after acetazolamide. Acta Physiol Scand. 1975;93:385-390. [Medline] [Order article via Infotrieve]
20. Vorstrup S, Jensen KE, Thomsen C, Henriksen O, Lassen NA, Paulson OB. Neuronal pH regulation: constant normal intracellular pH is maintained in brain during low extracellular pH induced by acetazolamide: 31P NMR study. J Cereb Blood Flow Metab. 1989;9:417-427. [Medline] [Order article via Infotrieve]
21.
Bickler PE, Litt L, Banville DL, Severinghaus
JW. Effect of acetazolamide on cerebral
acid-base balance. J Appl Physiol. 1988;65:422-427.
22. Lassen NA. Hypothesis: is central chemoreceptor sensitive to intracellular rather than extracellular pH? Clin Physiol. 1990;10:311-319. [Medline] [Order article via Infotrieve]
23. Ridderstråle Y, Hanson M. Histochemical study of the distribution of carbonic anhydrase in the cat brain. Acta Physiol Scand. 1985;124:557-564. [Medline] [Order article via Infotrieve]
24.
Hanson MA, Nye PCG, Torrance RW. The location of
carbonic anhydrase in relation to the blood-brain barrier at the
medullary chemoreceptors of the cat. J
Physiol. 1981;320:113-125.
25. Maren TH, Robinson B. The pharmacology of acetazolamide as related to cerebrospinal fluid and the treatment of hydrocephalus. Bull Johns Hopkins Hosp. 1960;106:1-24. [Medline] [Order article via Infotrieve]
26. Lehmann B, Linner E, Wistrand PJ. The pharmacokinetics of acetazolamide in relation to its use in the treatment of glaucoma and its effects as an inhibitor of carbonic anhydrases. Adv Biosci. 1970;5:197-219.
27. Kunka RL, Mattocks AM. Nonlinear model for acetazolamide. J Pharm Sci. 1979;68:342-346. [Medline] [Order article via Infotrieve]
28. Dahl A, Russell D, Nyberg-Hansen R, Rootwelt K, Mowinkel P. Simultaneous assessment of vasoreactivity using transcranial Doppler ultrasound and cerebral blood flow in healthy subjects. J Cereb Blood Flow Metab. 1994;14:974-981. [Medline] [Order article via Infotrieve]
29. Lassen NA. Cerebral blood flow tomography with xenon-133. Semin Nucl Med. 1985;15:347-356. [Medline] [Order article via Infotrieve]
30. Dahl A, Russell D, Nyberg-Hansen R, Rootwelt K. Cluster headache: transcranial Doppler ultrasound and rCBF studies. Cephalalgia. 1990;10:87-94. [Medline] [Order article via Infotrieve]
31.
Højer-Pedersen E. Effect of
acetazolamide on cerebral blood flow in subacute and
chronic cerebrovascular disease. Stroke. 1987;18:887-891.
32.
Yamamoto M, Meyer JS, Sakai F, Yamaguchi F.
Aging and cerebral vasodilator responses to hypercarbia: responses in
normal aging and in persons with risk factors for stroke.
Arch Neurol.. 1980;37:489-496.
33. Ackerman RH, Zilkha E, Bull JWD, Du Boulay GH, Marshall J, Ross Russell WA, Symon L. The relationship of the CO2 reactivity of cerebral vessels to blood pressure and mean resting blood flow. Neurology. 1973;23;21-26.
This article has been cited by other articles:
 |
|
 |
|
  P. Neu, P. Schlattmann, A. Schilling, and A. Hartmann Cerebrovascular Reactivity in Major Depression: A Pilot Study Psychosom Med, January 1, 2004; 66(1): 6 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chabriat, S. Pappata, L. Ostergaard, C. A. Clark, M. Pachot-Clouard, K. Vahedi, A. Jobert, D. Le Bihan, and M. G. Bousser Cerebral Hemodynamics in CADASIL Before and After Acetazolamide Challenge Assessed With MRI Bolus Tracking Stroke, August 1, 2000; 31(8): 1904 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Schreiber, S. Gottschalk, M. Weih, A. Villringer, and J. M. Valdueza Assessment of Blood Flow Velocity and Diameter of the Middle Cerebral Artery during the Acetazolamide Provocation Test by Use of Transcranial Doppler Sonography and MR Imaging AJNR Am. J. Neuroradiol., July 1, 2000; 21(7): 1207 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Molina, J. A. Sabin, J. Montaner, A. Rovira, S. Abilleira, and A. Codina Impaired Cerebrovascular Reactivity as a Risk Marker for First-Ever Lacunar Infarction : A Case-Control Study Stroke, November 1, 1999; 30 (11): 2296 - 2301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Eicke, E. Buss, R. R. Bahr, G. Hajak, and W. Paulus Influence of Acetazolamide and CO2 on Extracranial Flow Volume and Intracranial Blood Flow Velocity Stroke, January 1, 1999; 30(1): 76 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Gur, I. Bova, and N. M. Bornstein Is Impaired Cerebral Vasomotor Reactivity a Predictive Factor of Stroke in Asymptomatic Patients? Stroke, December 1, 1996; 27(12): 2188 - 2190. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||